AI assistant
Sending…
REPLIGEN CORP — Director's Dealing 2025
Dec 17, 2025
30826_dirs_2025-12-17_2658c442-bee5-40b3-b57f-3b6c12e66f94.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2025-12-16
Reporting Person: MUIR GLENN P (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | Common Stock | M | 3366 | $26.12 | Acquired | 36622 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-16 | Stock Option (Right to Buy) | $26.12 | M | 3366 | Acquired | 2026-05-11 | Common Stock (3366) | Direct |
Footnotes
F1: This option is fully vested and exercisable.
More from REPLIGEN CORP
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 27
Annual Report
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 23
Director's Dealing
2026
Mar 23